AMPIO PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. AMPIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 9.08 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 38.71% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY15||Q3 FY14|
|Net Sales ($mil)||0.49||0.02|
|Net Income ($mil)||-7.37||-9.28|
|Balance Sheet||Q3 FY15||Q3 FY14|
|Cash & Equiv. ($mil)||35.39||56.83|
|Total Assets ($mil)||57.08||77.15|
|Total Debt ($mil)||4.83||0.0|
|Profitability||Q3 FY15||Q3 FY14|
|Gross Profit Margin||-1502.67||-44623.81|
|Return on Assets||-55.91||-46.08|
|Return on Equity||-71.04||-48.5|
|Debt||Q3 FY15||Q3 FY14|
|Share Data||Q3 FY15||Q3 FY14|
|Shares outstanding (mil)||52.0||51.97|
|Div / share||0.0||0.0|
|Book value / share||0.86||1.41|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||206315.0||434751.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.64 indicates valuation on par with the S&P 500 average of 2.51 and a significant discount versus the industry average of 7.00. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, AMPIO PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives within the industry.
|AMPE NM||Peers 27.42||AMPE NM||Peers 26.07|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AMPE's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AMPE's P/CF is negative making the measure meaningless.
|AMPE NA||Peers 14.46||AMPE NA||Peers 0.64|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AMPE 2.64||Peers 7.00||AMPE 19.74||Peers 20.80|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AMPE is trading at a significant discount to its peers.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AMPE is expected to keep pace with its peers on the basis of earnings growth.
|AMPE 164.66||Peers 13.10||AMPE 967.16||Peers 11.56|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AMPE is trading at a significant premium to its industry.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
AMPE has a sales growth rate that significantly exceeds its peers.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.